• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Deborah Schrag, MD, MPH


  • Wolpin BM, Rubinson DA, Wang X, Chan JA, Cleary JM, Enzinger PC, Fuchs CS, McCleary NJ, Meyerhardt JA, Ng K, Schrag D, Sikora AL, Spicer BA, Killion L, Mamon H, Kimmelman AC.Phase II and Pharmacodynamic Study of Autophagy Inhibition Using Hydroxychloroquine in Patients With Metastatic Pancreatic Adenocarcinoma.Oncologist. 2014 Jun;19(6):637-8.
  • Greenberg CC, Habel LA, Hughes ME, Nekhlyudov L, Achacoso N, Acton L, Schrag D, Jiang W, Edge S, Weeks JC, Punglia RS.Characterization and Treatment of Local Recurrence Following Breast Conservation for Ductal Carcinoma In Situ.Ann Surg Oncol. 2014 May 24.
  • Bestvina CM, Zullig LL, Rushing C, Chino F, Samsa GP, Altomare I, Tulsky J, Ubel P, Schrag D, Nicolla J, Abernethy AP, Peppercorn J, Zafar SY.Patient-oncologist cost communication, financial distress, and medication adherence.J Oncol Pract. 2014 May;10(3):162-7.
  • Arvold ND, Wang Y, Zigler C, Schrag D, Dominici F.Hospitalization burden and survival among older glioblastoma patients.Neuro Oncology. 2014 Apr 28.
  • Dodgion CM, Neville BA, Lipsitz SR, Schrag D, Breen E, Zinner MJ, Greenberg CC.Hospital variation in sphincter preservation for elderly rectal cancer patients.J Surg Res. 2014 Mar 22.
  • Wang Y, Schrag D, Brooks GA, Dominici F.National trends in pancreatic cancer outcomes and pattern of care among Medicare beneficiaries, 2000 through 2010.Cancer. 2014 Apr 1(7):1050-8.
  • Reyngold M, Niland J, ter Veer A, Milne D, Bekaii-Saab T, Cohen SJ, Lai L, Schrag D, Skibber JM, Small W, Weiser M, Wilkinson N, Goodman KA.Neoadjuvant radiotherapy use in locally advanced rectal cancer at NCCN member institutions.J Natl Compr Canc Netw. 2014 Feb;12(2):235-43.
  • Brooks GA, Abrams TA, Meyerhardt JA, Enzinger PC, Sommer K, Dalby CK, Uno H, Jacobson JO, Fuchs CS, Schrag D.Identification of potentially avoidable hospitalizations in patients with GI cancer.J Clin Oncol. 2014 Feb 20(6):496-503.
  • Schrag D, Weiser MR, Goodman KA, Gonen M, Hollywood E, Cercek A, Reidy-Lagunes DL, Gollub MJ, Shia J, Guillem JG, Temple LK, Paty PB, Saltz LB.Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial.J Clin Oncol. 2014 Feb 20;32(6):513-8.
  • Abrams TA, Meyer G, Schrag D, Meyerhardt JA, Moloney J, Fuchs CS.Chemotherapy usage patterns in a US-wide cohort of patients with metastatic colorectal cancer.Journal of the National Cancer Institute. 2014 Feb;106(2):djt371.
  • Hay JL, Atkinson TM, Reeve BB, Mitchell SA, Mendoza TR, Willis G, Minasian LM, Clauser SB, Denicoff A, O'Mara A, Chen A, Bennett AV, Paul DB, Gagne J, Rogak L, Sit L, Viswanath V, Schrag D, Basch E, .Cognitive interviewing of the US National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).Qual Life Res. 2014 Feb;23(1):257-69.
  • Warren JL, Mariotto A, Melbert D, Schrag D, Doria-Rose P, Penson D, Yabroff KR.Sensitivity of Medicare Claims to Identify Cancer Recurrence in Elderly Colorectal and Breast Cancer Patients.Med Care. 2013 Dec 26.
  • Meyerhardt JA, Mangu PB, Flynn PJ, Korde L, Loprinzi CL, Minsky BD, Petrelli NJ, Ryan K, Schrag DH, Wong SL, Benson AB, .Follow-up care, surveillance protocol, and secondary prevention measures for survivors of colorectal cancer: American Society of Clinical Oncology clinical practice guideline endorsement.J Clin Oncol. 2013 Dec 10;31(35):4465-70.
  • Rutter CM, Johnson EA, Feuer EJ, Knudsen AB, Kuntz KM, Schrag D.Secular trends in colon and rectal cancer relative survival.Journal of the National Cancer Institute. 2013 Dec 4;105(23):1806-13.
  • Martin MY, Fouad MN, Oster RA, Schrag D, Urmie J, Sanders S, Pisu M.What do cancer patients worry about when making decisions about treatment? Variation across racial/ethnic groups.Support Care Cancer. 2014 Jan;22(1):233-44.
  • Greenberg CC, Wind JK, Chang GJ, Chen RC, Schrag D.Stakeholder engagement for comparative effectiveness research in cancer care: experience of the DEcIDE Cancer Consortium.J Comp Eff Res. 2013 Mar;2(2):117-25.
  • Neuman HB, Weiss JM, Schrag D, Ronk K, Havlena J, LoConte NK, Smith MA, Greenberg CC.Patient demographic and tumor characteristics influencing oncologist follow-up frequency in older breast cancer survivors.Ann Surg Oncol. 2013 Dec;20(13):4128-36.
  • Shih YC, Ganz PA, Aberle D, Abernethy A, Bekelman J, Brawley O, Goodwin JS, Hu JC, Schrag D, Temel JS, Schnipper L.Delivering high-quality and affordable care throughout the cancer care continuum.J Clin Oncol. 2013 Nov 10;31(32):4151-7.
  • Elkin EB, Atoria CL, Leoce N, Bach PB, Schrag D.Changes in the availability of screening mammography, 2000-2010.Cancer. 2013 Nov 1;119(21):3847-53.
  • Schrag D.Evolving role of neoadjuvant therapy in rectal cancer.Curr Treat Options Oncol. 2013 Sep;14(3):350-64.
  • Chen AB, Cronin A, Weeks JC, Chrischilles EA, Malin J, Hayman JA, Schrag D.Expectations about the effectiveness of radiation therapy among patients with incurable lung cancer.J Clin Oncol. 2013 Jul 20;31(21):2730-5.
  • Mack JW, Chen K, Boscoe FP, Gesten FC, Roohan PJ, Weeks JC, Schymura MJ, Schrag D.Underuse of hospice care by Medicaid-insured patients with stage IV lung cancer in New York and California.J Clin Oncol. 2013 Jul 10;31(20):2569-79.
  • Judson TJ, Bennett AV, Rogak LJ, Sit L, Barz A, Kris MG, Hudis CA, Scher HI, Sabattini P, Schrag D, Basch E.Feasibility of long-term patient self-reporting of toxicities from home via the Internet during routine chemotherapy.J Clin Oncol. 2013 Jul 10;31(20):2580-5.
  • Soeteman DI, Stout NK, Ozanne EM, Greenberg C, Hassett MJ, Schrag D, Punglia RS.Modeling the effectiveness of initial management strategies for ductal carcinoma in situ.Journal of the National Cancer Institute. 2013 Jun 5;105(11):774-81.
  • Brooks GA, Li L, Sharma DB, Weeks JC, Hassett MJ, Yabroff KR, Schrag D.Regional variation in spending and survival for older adults with advanced cancer.Journal of the National Cancer Institute. 2013 May 1;105(9):634-42.
  • Elkin EB, Paige Nobles J, Pinheiro LC, Atoria CL, Schrag D.Changes in access to screening mammography, 2008-2011.Cancer Causes Control. 2013 May;24(5):1057-9.
  • Wolpin BM, Ng K, Zhu AX, Abrams T, Enzinger PC, McCleary NJ, Schrag D, Kwak EL, Allen JN, Bhargava P, Chan JA, Goessling W, Blaszkowsky LS, Supko JG, Elliot M, Sato K, Regan E, Meyerhardt JA, Fuchs CS.Multicenter Phase II Study of Tivozanib (AV-951) and Everolimus (RAD001) for Patients With Refractory, Metastatic Colorectal Cancer.Oncologist. 2013 Apr 11.
  • Zhu J, Sharma DB, Chen AB, Johnson BE, Weeks JC, Schrag D.Comparative effectiveness of three platinum-doublet chemotherapy regimens in elderly patients with advanced non-small cell lung cancer.Cancer. 2013 Apr 5.
  • Zafar SY, Peppercorn JM, Schrag D, Taylor DH, Goetzinger AM, Zhong X, Abernethy AP.The Financial Toxicity of Cancer Treatment: A Pilot Study Assessing Out-of-Pocket Expenses and the Insured Cancer Patient's Experience.Oncologist. 2013 Feb 26.
  • Abel GA, Chen K, Taback N, Hassett MJ, Schrag D, Weeks JC.Impact of oncology-related direct-to-consumer advertising: association with appropriate and inappropriate prescriptions.Cancer. 2013 Mar 1;119(5):1065-72.
  • Chen AB, Cronin A, Weeks JC, Chrischilles EA, Malin J, Hayman JA, Schrag D.Palliative radiation therapy practice in patients with metastatic non-small-cell lung cancer: a Cancer Care Outcomes Research and Surveillance Consortium (CanCORS) Study.J Clin Oncol. 2013 Feb 10;31(5):558-64.
  • Weeks JC, Mack JW, Schrag D.Talking with patients about dying.N Engl J Med. 2013 Jan 31;368(5):480-1.
  • McCleary NJ, Wigler D, Berry D, Sato K, Abrams T, Chan J, Enzinger P, Ng K, Wolpin B, Schrag D, Fuchs CS, Hurria A, Meyerhardt JA.Feasibility of computer-based self-administered cancer-specific geriatric assessment in older patients with gastrointestinal malignancy.Oncologist. 2013;18(1):64-72.
  • Sinclair AH, Schymura MJ, Boscoe FP, Yung RL, Chen K, Roohan P, Tai E, Schrag D.Measuring colorectal cancer care quality for the publicly insured in New York State.Cancer Med. 2012 Dec;1(3):363-71.
  • Dodgion CM, Neville BA, Lipsitz SR, Hu YY, Schrag D, Breen E, Greenberg CC.Do older Americans undergo stoma reversal following low anterior resection for rectal cancer?.J Surg Res. 2012 Dec 21.
  • Hassett MJ, Ritzwoller DP, Taback N, Carroll N, Cronin AM, Ting GV, Schrag D, Warren JL, Hornbrook MC, Weeks JC.Validating Billing/Encounter Codes as Indicators of Lung, Colorectal, Breast, and Prostate Cancer Recurrence Using 2 Large Contemporary Cohorts.Med Care. 2012 Dec 6.
  • Khrizman P, Niland JC, Ter Veer A, Milne D, Bullard Dunn K, Carson WE, Engstrom PF, Shibata S, Skibber JM, Weiser MR, Schrag D, Benson AB.Postoperative Adjuvant Chemotherapy Use in Patients With Stage II/III Rectal Cancer Treated With Neoadjuvant Therapy: A National Comprehensive Cancer Network Analysis.J Clin Oncol. 2012 Nov 19.
  • Knudsen AB, Hur C, Gazelle GS, Schrag D, McFarland EG, Kuntz KM.Rescreening of persons with a negative colonoscopy result: results from a microsimulation model.Ann Intern Med. 2012 Nov 6;157(9):611-20.
  • Feuer EJ, Lee M, Mariotto AB, Cronin KA, Scoppa S, Penson DF, Hachey M, Cynkin L, Carter GA, Campbell D, Percy-Laurry A, Zou Z, Schrag D, Hankey BF.The Cancer Survival Query System: Making survival estimates from the Surveillance, Epidemiology, and End Results program more timely and relevant for recently diagnosed patients.Cancer. 2012 Nov 15;118(22):5652-62.
  • Weeks JC, Catalano PJ, Cronin A, Finkelman MD, Mack JW, Keating NL, Schrag D.Patients' expectations about effects of chemotherapy for advanced cancer.N Engl J Med. 2012 Oct 25;367(17):1616-25.
  • Morikawa T, Tanaka N, Kuchiba A, Nosho K, Yamauchi M, Hornick JL, Swanson RS, Chan AT, Meyerhardt JA, Huttenhower C, Schrag D, Fuchs CS, Ogino S.Predictors of lymph node count in colorectal cancer resections: data from US nationwide prospective cohort studies.Arch Surg. 2012 Aug;147(8):715-23.
  • Yung RL, Hassett MJ, Chen K, Gesten FC, Roohan PJ, Boscoe FP, Sinclair AH, Schymura MJ, Schrag D.Initiation of adjuvant hormone therapy by Medicaid insured women with nonmetastatic breast cancer.Journal of the National Cancer Institute. 2012 Jul 18;104(14):1102-5.
  • Sanoff HK, Carpenter WR, Stürmer T, Goldberg RM, Martin CF, Fine JP, McCleary NJ, Meyerhardt JA, Niland J, Kahn KL, Schymura MJ, Schrag D.Effect of adjuvant chemotherapy on survival of patients with stage III colon cancer diagnosed after age 75 years.J Clin Oncol. 2012 Jul 20;30(21):2624-34.
  • Meyerhardt JA, Ancukiewicz M, Abrams TA, Schrag D, Enzinger PC, Chan JA, Kulke MH, Wolpin BM, Goldstein M, Blaszkowsky L, Zhu AX, Elliott M, Regan E, Jain RK, Duda DG.Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer.PLoS ONE. 2012;7(6):e38231.
  • Chan JA, Blaszkowsky LS, Enzinger PC, Ryan DP, Abrams TA, Zhu AX, Temel JS, Schrag D, Bhargava P, Meyerhardt JA, Wolpin BM, Fidias P, Zheng H, Florio S, Regan E, Fuchs CS.A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma.Ann Oncol. 2011 Jan 7.
  • Boscoe FP, Schrag D, Chen K, Roohan PJ, Schymura MJ.Building Capacity to Assess Cancer Care in the Medicaid Population in New York State.Health Serv Res. 2010 Dec 15.
  • Sima CS, Panageas KS, Schrag D.Cancer screening among patients with advanced cancer.JAMA. 2010 Oct 13;304(14):1584-91.
  • Kindler HL, Niedzwiecki D, Hollis D, Sutherland S, Schrag D, Hurwitz H, Innocenti F, Mulcahy MF, O'Reilly E, Wozniak TF, Picus J, Bhargava P, Mayer RJ, Schilsky RL, Goldberg RM.Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303).J Clin Oncol. 2010 Aug 1;28(22):3617-22.
  • Ng K, Schrag D.Microsatellite Instability and Adjuvant Fluorouracil Chemotherapy: A Mismatch?.J Clin Oncol. 2010 Jul 10;28(20):3207-10.
  • Chou JF, Row D, Gonen M, Liu YH, Schrag D, Weiser MR.Clinical and pathologic factors that predict lymph node yield from surgical specimens in colorectal cancer: a population-based study.Cancer. 2010 Jun 1;116(11):2560-70.
  • Elkin EB, Ishill NM, Snow JG, Panageas KS, Bach PB, Liberman L, Wang F, Schrag D.Geographic Access and the Use of Screening Mammography.Med Care. 2010 Apr;48(4):349-56.
  • Kahn KL, Adams JL, Weeks JC, Chrischilles EA, Schrag D, Ayanian JZ, Kiefe CI, Ganz PA, Bhoopalam N, Potosky AL, Harrington DP, Fletcher RH.Adjuvant chemotherapy use and adverse events among older patients with stage III colon cancer.JAMA. 2010 Mar 17;303(11):1037-45.
  • Jang TL, Bekelman JE, Liu Y, Bach PB, Basch EM, Elkin EB, Zelefsky MJ, Scardino PT, Begg CB, Schrag D.Physician visits prior to treatment for clinically localized prostate cancer.Arch Intern Med. 2010 Mar 8;170(5):440-50.
  • Wong SL, Mangu PB, Choti MA, Crocenzi TS, Dodd GD, Dorfman GS, Eng C, Fong Y, Giusti AF, Lu D, Marsland TA, Michelson R, Poston GJ, Schrag D, Seidenfeld J, Benson AB.American Society of Clinical Oncology 2009 clinical evidence review on radiofrequency ablation of hepatic metastases from colorectal cancer.J Clin Oncol. 2010 Jan 20;28(3):493-508. Review.
  • Sima CS, Panageas KS, Heller G, Schrag D.Analytical strategies for characterizing chemotherapy diffusion with patient-level population-based data.Appl Health Econ Health Policy. 2010;8(1):37-51.
  • Gönen M, Schrag D, Weiser MR.Nodal staging score: a tool to assess adequate staging of node-negative colon cancer.J Clin Oncol. 2009 Dec 20;27(36):6166-71.
  • Basch E, Jia X, Heller G, Barz A, Sit L, Fruscione M, Appawu M, Iasonos A, Atkinson T, Goldfarb S, Culkin A, Kris MG, Schrag D.Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes.Journal of the National Cancer Institute. 2009 Dec 2;101(23):1624-32.
  • Greenberg CC, Ashley SW, Schrag D.Centralization of cancer surgery: what does it mean for surgical training?.J Clin Oncol. 2009 Oct 1;27(28):4637-9.
  • Romanus D, Weiser MR, Skibber JM, Ter Veer A, Niland JC, Wilson JL, Rajput A, Wong YN, Benson AB, Shibata S, Schrag D.Concordance with NCCN Colorectal Cancer Guidelines and ASCO/NCCN Quality Measures: an NCCN institutional analysis.J Natl Compr Canc Netw. 2009 Sep;7(8):895-904.
  • Yabroff KR, Schrag D.Challenges and opportunities for use of cost-effectiveness analysis.Journal of the National Cancer Institute. 2009 Sep 2;101(17):1161-3.
  • Schrag D, Virnig BA, Warren JL.Linking tumor registry and Medicaid claims to evaluate cancer care delivery.Health Care Financ Rev. 2009;30(4):61-73.
  • Meropol NJ, Schrag D, Smith TJ, Mulvey TM, Langdon RM, Blum D, Ubel PA, Schnipper LE, .American Society of Clinical Oncology guidance statement: the cost of cancer care.J Clin Oncol. 2009 Aug 10;27(23):3868-74.
  • Temple LK, Romanus D, Niland J, Veer AT, Weiser MR, Skibber J, Wilson J, Rajput A, Benson A, Wong YN, Schrag D.Factors associated with sphincter-preserving surgery for rectal cancer at national comprehensive cancer network centers.Ann Surg. 2009 Aug;250(2):260-7.
  • Yabroff KR, Warren JL, Schrag D, Mariotto A, Meekins A, Topor M, Brown ML.Comparison of approaches for estimating incidence costs of care for colorectal cancer patients.Med Care. 2009 Jul;47(7 Suppl 1):S56-63.
  • Yabroff KR, Warren JL, Banthin J, Schrag D, Mariotto A, Lawrence W, Meekins A, Topor M, Brown ML.Comparison of approaches for estimating prevalence costs of care for cancer patients: what is the impact of data source?.Med Care. 2009 Jul;47(7 Suppl 1):S64-9.
  • Tew WP,Radovich D,O'Reilly E,Schwartz G,Schrag D,Saltz LB,Kelsen DP,Kepler S,Ilson DH.Phase I trial of weekly cisplatin, irinotecan and paclitaxel in patients with advanced gastrointestinal cancer.Invest New Drugs. 2009 Aug;27(4):366-73.
  • Wideroff L,Phillips KA,Randhawa G,Ambs A,Armstrong K,Bennett CL,Brown ML,Donaldson MS,Follen M,Goldie SJ,Hiatt RA,Khoury MJ,Lewis G,McLeod HL,Piper M,Powell I,Schrag D,Schulman KA,Scott J.A health services research agenda for cellular, molecular and genomic technologies in cancer care.Public Health Genomics. 2009;12(4):233-44. Review.
  • Phelps AC,Maciejewski PK,Nilsson M,Balboni TA,Wright AA,Paulk ME,Trice E,Schrag D,Peteet JR,Block SD,Prigerson HG.Religious coping and use of intensive life-prolonging care near death in patients with advanced cancer.JAMA. 2009 Mar 18;301(11):1140-7.
  • Schrag D.Evaluating the impact of organizational changes in health care delivery: challenges in study design.J Clin Oncol. 2009 Apr 10;27(11):1744-5.
  • Pham HH,O'Malley AS,Bach PB,Saiontz-Martinez C,Schrag D.Primary care physicians' links to other physicians through Medicare patients: the scope of care coordination.Ann Intern Med. 2009 Feb 17;150(4):236-42.
  • Ku GY,O'Reilly EM,Saltz LB,Schrag D,Maki RG,Kelsen DP,Ilson DH.Phase I study of weekly cisplatin, bolus fluorouracil and escalating doses of irinotecan in advanced solid tumors.Cancer Invest. 2009 May;27(4):402-6.
  • Desch CE,McNiff KK,Schneider EC,Schrag D,McClure J,Lepisto E,Donaldson MS,Kahn KL,Weeks JC,Ko CY,Stewart AK,Edge SB.American Society of Clinical Oncology/National Comprehensive Cancer Network Quality Measures.J Clin Oncol. 2008 Jul 20;26(21):3631-7.
  • Elkin EB,Ishill N,Riley GF,Bach PB,Gonen M,Begg CB,Schrag D.Disenrollment from Medicare managed care among beneficiaries with and without a cancer diagnosis.Journal of the National Cancer Institute. 2008 Jul 16;100(14):1013-21.
  • Quah HM, Chou JF, Gonen M, Shia J, Schrag D, Saltz LB, Goodman KA, Minsky BD, Wong WD, Weiser MR.Pathologic stage is most prognostic of disease-free survival in locally advanced rectal cancer patients after preoperative chemoradiation.Cancer. 2008 Jul 1;113(1):57-64.
  • Schrag D.Enhancing cancer registry data to promote rational health system design.Journal of the National Cancer Institute. 2008 Mar 19;100(6):378-9.
  • Iasonos A, Schrag D, Raj GV, Panageas KS.How to build and interpret a nomogram for cancer prognosis.J Clin Oncol. 2008 Mar 10;26(8):1364-70. Review.
  • Quah HM, Chou JF, Gonen M, Shia J, Schrag D, Landmann RG, Guillem JG, Paty PB, Temple LK, Wong WD, Weiser MR.Identification of Patients with High-Risk Stage II Colon Cancer for Adjuvant Therapy.Dis Colon Rectum. 2008 May;51(5):503-7.
  • Vickers AJ, Bianco FJ, Gonen M, Cronin AM, Eastham JA, Schrag D, Klein EA, Reuther AM, Kattan MW, Pontes JE, Scardino PT.Effects of pathologic stage on the learning curve for radical prostatectomy: evidence that recurrence in organ-confined cancer is largely related to inadequate surgical technique.Eur Urol. 2008 May;53(5):960-6.
  • Weiser MR, Landmann RG, Kattan MW, Gonen M, Shia J, Chou J, Paty PB, Guillem JG, Temple LK, Schrag D, Saltz LB, Wong WD.Individualized prediction of colon cancer recurrence using a nomogram.J Clin Oncol. 2008 Jan 20;26(3):380-5.
  • Roohipour R, Patil S, Goodman KA, Minsky BD, Wong WD, Guillem JG, Paty PB, Weiser MR, Neuman HB, Shia J, Schrag D, Temple LK.Squamous-cell carcinoma of the anal canal: predictors of treatment outcome.Dis Colon Rectum. 2008 Feb;51(2):147-53.
  • Basch E, Iasonos A, Barz A, Culkin A, Kris MG, Artz D, Fearn P, Speakman J, Farquhar R, Scher HI, McCabe M, Schrag D.Long-term toxicity monitoring via electronic patient-reported outcomes in patients receiving chemotherapy.J Clin Oncol. 2007 Dec 1;25(34):5374-80.
  • Elkin EB, Kim SH, Casper ES, Kissane DW, Schrag D.Desire for information and involvement in treatment decisions: elderly cancer patients' preferences and their physicians' perceptions.J Clin Oncol. 2007 Nov 20;25(33):5275-80.
  • Bekelman JE, Zelefsky MJ, Jang TL, Basch EM, Schrag D.Variation in adherence to external beam radiotherapy quality measures among elderly men with localized prostate cancer.Int J Radiat Oncol Biol Phys. 2007 Dec 1;69(5):1456-66.
  • Nahas CS, Shia J, Joseph R, Schrag D, Minsky BD, Weiser MR, Guillem JG, Paty PB, Klimstra DS, Tang LH, Wong WD, Temple LK.Squamous-cell carcinoma of the rectum: a rare but curable tumor.Dis Colon Rectum. 2007 Sep;50(9):1393-400.
  • Vickers AJ, Bianco FJ, Serio AM, Eastham JA, Schrag D, Klein EA, Reuther AM, Kattan MW, Pontes JE, Scardino PT.The surgical learning curve for prostate cancer control after radical prostatectomy.Journal of the National Cancer Institute. 2007 Aug 1;99(15):1171-7.
  • Klabunde CN, Legler JM, Warren JL, Baldwin LM, Schrag D.A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients.Ann Epidemiol. 2007 Aug;17(8):584-90.
  • O'Malley AS, Pham HH, Schrag D, Wu B, Bach PB.Potentially avoidable hospitalizations for COPD and pneumonia: the role of physician and practice characteristics.Med Care. 2007 Jun;45(6):562-70.
  • Panageas KS, Ben-Porat L, Dickler MN, Chapman PB, Schrag D.When you look matters: the effect of assessment schedule on progression-free survival.J Natl Cancer Inst. 2007 Mar 21;99(6):428-32.
  • Pham HH, Schrag D, O'Malley AS, Wu B, Bach PB.Care patterns in Medicare and their implications for pay for performance.N Engl J Med. 2007 Mar 15;356(11):1130-9.
  • Schrag D, Hanger M.Medical oncologists' views on communicating with patients about chemotherapy costs: a pilot survey.J Clin Oncol. 2007 Jan 10;25(2):233-7. Review.
  • Ballas LK, Elkin EB, Schrag D, Minsky BD, Bach PB.Radiation therapy facilities in the United States.Int J Radiat Oncol Biol Phys. 2006 Nov 15;66(4):1204-11.
  • Basch E, Iasonos A, McDonough T, Barz A, Culkin A, Kris MG, Scher HI, Schrag D.Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study.Lancet Oncol. 2006 Nov;7(11):903-9.
  • Panageas KS, Schrag D, Russell Localio A, Venkatraman ES, Begg CB.Properties of analysis methods that account for clustering in volume-outcome studies when the primary predictor is cluster size.Stat Med. 2007 Apr 30;26(9):2017-35.
  • Vogelaar I, van Ballegooijen M, Schrag D, Boer R, Winawer SJ, Habbema JD, Zauber AG.How much can current interventions reduce colorectal cancer mortality in the U.S.? Mortality projections for scenarios of risk-factor modification, screening, and treatment.Cancer. 2006 Oct 1;107(7):1624-33.
  • Bekelman JE, Rosenzweig KE, Bach PB, Schrag D.Trends in the use of postoperative radiotherapy for resected non-small-cell lung cancer.Int J Radiat Oncol Biol Phys. 2006 Oct 1;66(2):492-9.
  • Elkin EB, Hurria A, Mitra N, Schrag D, Panageas KS.Adjuvant chemotherapy and survival in older women with hormone receptor-negative breast cancer: assessing outcome in a population-based, observational cohort.J Clin Oncol. 2006 Jun 20;24(18):2757-64.
  • Paskett ED, Schrag D, Kornblith A, Lamont EB, Weeks JC, Marshall JR, Shapiro C, Holland J.Cancer and leukemia group B cancer control and health outcomes committee: origins and accomplishments.Clin Cancer Res. 2006 Jun 1;12(11 Pt 2):3601s-5s. Review.
  • Schrag D, Xu F, Hanger M, Elkin E, Bickell NA, Bach PB.Fragmentation of care for frequently hospitalized urban residents.Med Care. 2006 Jun;44(6):560-7.
  • Bickell NA, Wang JJ, Oluwole S, Schrag D, Godfrey H, Hiotis K, Mendez J, Guth AA.Missed opportunities: racial disparities in adjuvant breast cancer treatment.J Clin Oncol. 2006 Mar 20;24(9):1357-62.
  • Earle CC, Schrag D, Neville BA, Yabroff KR, Topor M, Fahey A, Trimble EL, Bodurka DC, Bristow RE, Carney M, Warren JL.Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients.J Natl Cancer Inst. 2006 Feb 1;98(3):172-80.
  • Schrag D, Earle C, Xu F, Panageas KS, Yabroff KR, Bristow RE, Trimble EL, Warren JL.Associations between hospital and surgeon procedure volumes and patient outcomes after ovarian cancer resection.J Natl Cancer Inst. 2006 Feb 1;98(3):163-71.
  • Indurkhya A, Mitra N, Schrag D.Using propensity scores to estimate the cost-effectiveness of medical therapies.Stat Med. 2006 May 15;25(9):1561-76.